Title
Category
Credits
Event date
Cost
Gas Station Drugs: Emerging Substances, Hidden Risks, and Community Impact
  • COACH
  • 1.20 ABN
  • 1.00 ABSWE
  • 1.00 ACPE Pharmacy
  • 1.00 BDEA
04/08/2026
$0.00
The sale of unregulated and often mislabeled substances—commonly referred to as “gas station drugs”—has expanded rapidly in convenience stores and vape shops. Marketed as legal alternatives or wellness products, these substances often contain psychoactive ingredients that pose significant risks to physical and mental health. This webinar will examine the evolving landscape of gas station drugs, including kratom, delta‑8 and delta- 9 products, and other emerging substances.
Vaping Exposed: Health Risks, Youth Trends, and Prevention Strategies
  • COACH
  • 1.20 ABN
  • 1.00 ABSWE
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 BDEA
04/22/2026
$0.00
Vaping has become one of the most prevalent forms of substance use among adolescents and young adults, driven by appealing flavors, targeted marketing, and widespread misinformation regarding safety. Despite its popularity, vaping is associated with significant respiratory, cardiovascular, and neurological risks, as well as an increased likelihood of transitioning to other substance use. This webinar will explore current trends in vaping, including nicotine and THC products, their health impacts, and the unique vulnerabilities of youth populations.
Opioids and Naloxone: Overdose Recognition, Response, and Prevention
  • COACH
  • 1.20 ABN
  • 1.00 ABSWE
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 BDEA
05/20/2026
$0.00
The opioid crisis continues to impact individuals, families, and communities. Timely naloxone administration has proven to be one of the most effective tools in preventing fatal opioid overdoses, yet barriers to access, education, and stigma persist. This webinar will provide an overview of the current opioid landscape, including overdose trends and risk factors. Participants will learn how to recognize an opioid overdose and understand how naloxone works.
Medical Cannabis in Clinical Practice: Evidence, Applications, and Cautions
  • COACH
  • 1.20 ABN
  • 1.00 ABSWE
  • 1.00 ACPE Pharmacy
  • 1.00 ACPE Technician
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 BDEA
06/03/2026
$0.00
Medical cannabis has gained increasing acceptance as a potential therapeutic option for a range of medical and behavioral health conditions. This session provides an evidence-based overview of medical cannabis, including its pharmacology, approved and off-label clinical indications, and known benefits and limitations. Participants will review current evidence regarding efficacy, safety concerns, and potential adverse effects, as well as variability in products, dosing challenges, and drug–drug interactions.
Strengthening Community-Based Prevention: Strategies for Addressing Substance Misuse in Alabama
  • COACH
  • 3.60 ABN
  • 3.00 ABSWE
  • 3.00 ACPE Pharmacy
  • 3.00 ACPE Technician
  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 BDEA
06/30/2026
$0.00
This three-hour continuing education program equips Alabama’s mental health, healthcare, and community-based professionals with practical strategies to strengthen substance misuse prevention efforts. Through a combination of presentations and interactive breakout sessions, participants will explore current drug trends, medical cannabis considerations, and naloxone use alongside critical prevention competencies such as reducing stigma, understanding community norms, and applying accessible tools for data collection and evaluation.
2026 APhA Pharmacy-Based Immunization Delivery Certificate Training Program - Pharmacists
  • APhA
07/29/2026
$400.00
APhA’s Pharmacy-Based Immunization Delivery certificate training program is based on national educational standards for immunization training from the CDC. This practice-based curriculum represents a fusion of science and clinical pharmacy. The program, which emphasizes a health care team approach, seeks to foster the implementation of interventions that will promote disease prevention and public health.
Buprenorphine for Opioid Use Disorder: Clinical Effectiveness, Safety, and Access
  • COACH
  • 1.00 ABN
  • 1.00 ABSWE
  • 1.00 ACPE Pharmacy
  • 1.00 ACPE Technician
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 BDEA
08/12/2026
$0.00
Buprenorphine is a cornerstone medication for the treatment of opioid use disorder (OUD) and plays a critical role in reducing overdose risk and improving treatment retention. This session provides an overview of buprenorphine’s pharmacology, effectiveness, and role within evidence-based OUD treatment. Participants will review initiation strategies, maintenance therapy, and considerations for special populations. The session will also explore safety issues, diversion concerns, stigma, regulatory changes, and interdisciplinary collaboration to improve patient access and outcomes.

Pages